Abstracts tagged "gout"

Abstract Number: 1186 • 2013 ACR/ARHP Annual Meeting
Use Of High-Dose Allopurinol To Reach Serum Uric Acid Targets In Patients With Gout Across Multiple Countries
Jasvinder A. Singh¹, Chris Storgard², Scott Baumgartner³ and Robert Morlock⁴, ¹Department of Medicine, University of Alabama, Tuscaloosa, AL, ²4939 Directors Place, Ardea Bioscience, San Diego, CA, ³Ardea Biosciences, San Diego, CA, ⁴Ardea Bioscience, San Diego, CA
Background/Purpose: Allopurinol is the most commonly used urate-lowering therapy (ULT) in the world. Although allopurinol is FDA approved for up to 800 mg/d and EMEA…
Abstract Number: 1987 • 2013 ACR/ARHP Annual Meeting
LIVER Outcomes In Gout Patients Treated With Febuxostat and Altered LIVER Function TESTS
Fernando Perez-Ruiz^1,2 and Ana M. Herrero-Beites^2,3, ¹Servicio de Reumatologia, Hospital Universitario Cruces, Baracaldo, Spain, ²BioCruces Health Research Institute, Baracaldo, Spain, ³Physical Medicine Division, Hospital de Gorliz, Gorliz, Spain
LIVER OUTCOMES IN GOUT PATIENTS TREATED WITH FEBUXOSTAT AND ALTERED LIVER FUNCTION TESTSBackground/Purpose: patients with significantly altered liver function test (LFTs) at screening do not…
Abstract Number: 1187 • 2013 ACR/ARHP Annual Meeting
A Large-Scale, Multicenter, Prospective, Open-Label, 6-Month Study To Evaluate The Safety Of Allopurinol Monotherapy In Patients With Gout
Michael A. Becker¹, David Fitz-Patrick², Chris Storgard³, Matt Cravets⁴ and Scott Baumgartner⁵, ¹Medicine, University of Chicago, Chicago, IL, ²East-West Medical Research Institute, Honolulu, HI, ³4939 Directors Place, Ardea Bioscience, San Diego, CA, ⁴Ardea Biosciences, Inc., San Diego, CA, ⁵Ardea Biosciences, San Diego, CA
Background/Purpose: Documentation of the safety profile of allopurinol at doses ≥300 mg/day is important for its ongoing use as first-line monotherapy or in combination with…
Abstract Number: 1988 • 2013 ACR/ARHP Annual Meeting
Self-Reported Gout, Comorbidities and Healthcare Resource Utilization Data From The 2012 United States National Health and Wellness Survey
Jasvinder A. Singh¹, Kathy Annunziata² and Puja Khanna³, ¹Department of Medicine, University of Alabama, Tuscaloosa, AL, ²Kantar Health, Princeton, NJ, ³Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI
Background/Purpose: Hyperuricemia and gout are associated with major cardiovascular and metabolic comorbidities. Recently published data on comorbidities and gout epidemiology in the US have been…
Abstract Number: 1188 • 2013 ACR/ARHP Annual Meeting
An Assessment Of The Response Of Chronic, Occult, Synovial-Based Inflammation Of Gout To Serum Urate Lowering Therapy
John D. Carter¹, Michelle Patelli², Scott Anderson², Neelish Prakash², Robyn Aydelott², Ernesto Rodriguez², Helen E. Bateman³, Ashley G. Sterrett⁴, Joanne Valeriano-Marcet⁵ and Louis R. Ricca⁶, ¹Internal Medicine; Division of Rheumatology, University of South Florida, Tampa, FL, ²University of South Florida, Tampa, FL, ³Medicine / Rheumatology (111K), James A Haley VA Hospital USF, Tampa, FL, ⁴Internal Medicine/Rheumatology, JAHVA, Tampa, FL, ⁵Internal Medicine, University of South Florida, Tampa, FL, ⁶University of South Florida College of Medicine, St Petersburg, FL
Background/Purpose: We recently demonstrated that synovitis is present in the vast majority of patients with inter-critical gout and that the severity of this synovitis did…
Abstract Number: 1873 • 2013 ACR/ARHP Annual Meeting
Use Of Mendelian Randomization Associates Increased Serum Urate Caused By Genetic Variation In Uric Acid Transporters With Improved Renal Function
Tony R. Merriman¹, Tanya Flynn², Janak de Zoysa³, Nicola Dalbeth⁴ and Kim Hughes², ¹Department of Biochemistry, University of Otago, Dunedin, New Zealand, ²University of Otago, Dunedin, New Zealand, ³Waitemata District Health Board, Auckland, New Zealand, ⁴Medicine, University of Auckland, Auckland, New Zealand
Background/Purpose: Hyperuricemia is the central risk factor for gout. In observational studies hyperuricemia also predicts the development and progression of chronic kidney disease independent of…
Abstract Number: 1189 • 2013 ACR/ARHP Annual Meeting
Allopurinol Dose Titration and Efficacy: A Large-Scale, 6-Month, Multicenter, Prospective Study
Scott Baumgartner¹, Hyon Choi^2,3, Nicola Dalbeth⁴, David Fitz-Patrick⁵, Matt Cravets⁶ and Chris Storgard⁷, ¹Ardea Biosciences, San Diego, CA, ²Section of Rheumatology and the Clinical Epidemiology, Boston University School of Medicine, Boston, MA, ³Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Auckland District Health Board, Auckland, New Zealand, ⁵East-West Medical Research Institute, Honolulu, HI, ⁶Ardea Biosciences, Inc., San Diego, CA, ⁷4939 Directors Place, Ardea Bioscience, San Diego, CA
Background/Purpose: Allopurinol is the first-line urate-lowering therapy (ULT) for most people with gout, but target serum uric acid (sUA) levels of 200-300 >300-400 >400-500 >500-600…
Abstract Number: 160 • 2013 ACR/ARHP Annual Meeting
Association Analysis Of The Organic Anion Transporter 4 and Urate Transporter 1 Locus With Gout In New Zealand Case-Control Sample Sets Reveals Multiple Ancestral-Specific Effects
Tony R. Merriman¹, Amanda Phipps-Green¹, Jade E. Hollis-Moffatt², Marilyn E. Merriman¹, Ruth Topless¹, Grant Montgomery³, Brett Chapman³, Lisa K. Stamp⁴, Nicola Dalbeth⁵ and Tanya Flynn², ¹Department of Biochemistry, University of Otago, Dunedin, New Zealand, ²University of Otago, Dunedin, New Zealand, ³Queensland Institute of Medical Research, Brisbane, Australia, ⁴University of Otago, Christchurch, New Zealand, ⁵Medicine, University of Auckland, Auckland, New Zealand
Background/Purpose: There are genetic variants in urate transporters SLC22A11 (OAT4) and SLC22A12 (URAT1) that influence serum urate levels in European Caucasian. However, there is no…
Abstract Number: 1723 • 2013 ACR/ARHP Annual Meeting
Lesinurad, An Inhibitor Of The Uric Acid Transporter URAT1 and a Potential Therapy For Gout, Requires URAT1 Phenylalanine 365 For High Affinity Inhibition
Philip K. Tan, David Hyndman and Jeffrey N. Miner, Ardea Biosciences, Inc., San Diego, CA
Background/Purpose: Gout is caused by a lack of efficient excretion of uric acid, resulting in hyperuricemia and the formation of crystal deposits of uric acid. …
Abstract Number: 1190 • 2013 ACR/ARHP Annual Meeting
The Synergistic Effects Of Metabolic Syndrome Indicators and Hyperuricemia In Contributing To Cardiac Event Risk: A Cross-Sectional Examination Of The Nhanes III Data
Daniel A. Albert^1,2 and Sayyad Kyazimzade³, ¹Medicine/Rheumatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, ²Rheumatology, The Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, NH, ³The Dartmouth Institute for Health Policy & Clinical Practice, Lebanon, NH, Lebanon, NH
Background/Purpose: The focus of this project is to assess the contribution of hyperuricemia and gout to the risk for cardiovascular events. In a preliminary analysis…
Abstract Number: 163 • 2013 ACR/ARHP Annual Meeting
The Frequency Of Single Nucleotide Polymorphisms In Urate Transporter Genes and Their Association With Uric Acid Concentration Based On Data From Genome-Wide Association Studies In The Korean Population
Chan-Nam Son¹, So-Young Bang², Sang-Cheol Bae³ and Jae-Bum Jun³, ¹Internal Medicine, Keimyung University Dongsan Medical Center, Daegu, South Korea, ²Department of Rheumatology, Hanyang University Guri Hospital, Guri, South Korea, ³Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
Background/Purpose: Gouty arthritis is characterized by hyperuricemia, which results from overproduction of, or impaired renal excretion of, uric acid. Recently, interest has increased in renal…
Abstract Number: 1721 • 2013 ACR/ARHP Annual Meeting
A Prediction Tool for Incident Gout Among Those With Hyperuricemia
Liseth Siemons¹ and Eswar Krishnan², ¹Department of Psychology, Health & Technology, University of Twente, Enschede, Netherlands, ²Medicine, Stanford University, Palo Alto, CA
Background/Purpose: The most common form of inflammatory arthritis observed in men is gout, a condition characterized by hyperuricemia and deposition of uric acid crystals in…
Abstract Number: 1192 • 2013 ACR/ARHP Annual Meeting
Pharmacovigilance Update On Pegloticase For Treatment Refractory Gout: United States Clinical Experience Demonstrates The Value Of Serum Uric Acid Monitoring As a Biomarker Of Risk and Efficacy
Robert T. Keenan¹, Raymond L. Malamet², Tina L. Howson³ and Kenneth M. Bahrt⁴, ¹Rheumatology, Duke University, Durham, NC, ²Global Medical Affairs, Savient Pharmaceuticals, Inc., Bridgewater, NJ, ³Savient Pharmaceuticals, Inc., Bridgewater, NJ, ⁴Medical Affairs, Savient Pharmaceuticals, Inc., Bridgewater, NJ
Background/Purpose: Pegloticase was approved in the US in late 2010 for patients with chronic gout refractory to xanthine oxidase inhibitors (XOIs). The clinical development program…
Abstract Number: 170 • 2013 ACR/ARHP Annual Meeting
Association Of BMI, 8 SNPs Reported To Be Related To Gout Phenotype and Their Interaction In Gout Incidence In Framingham Heart Study
Jasvinder A. Singh^1,2, Ana Vazquez³, Richard Reynolds³, Vinodh Srinivasasainagendra⁴, S. Louis Bridges Jr.⁵ and David Allison³, ¹Rheumatology, Birmingham VA, Birmingham, AL, ²Department of Medicine, University of Alabama, Tuscaloosa, AL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴University of alabama at birmingham, birmingham, AL, ⁵Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: We aim to assess the association of 8 serum urate SNPs and BMI and their interactions with incident gout in a population-based cohort study. Methods:…
Abstract Number: 1194 • 2013 ACR/ARHP Annual Meeting
Enhanced IL-1β and IL-6 Production In Gout Patients Upon Stimulation With Mono Sodium Urate Crystals and Synergizing Agents Compared To Healthy Volunteers
Tania O. Crisan¹, Maartje Cleophas¹, Mihai G. Netea¹, Tim L. Jansen² and Leo A. Joosten³, ¹Department of Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Department of Medicine, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands
Background/Purpose: Gout is an autoinflammatory disease characterized by the deposition of monosodium urate (MSU) crystals in the joints of hyperuricaemic patients and subsequent attacks of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].